Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
Globe Newswire•04/11/2026•09:15 ET
0
Key Highlights
- ➤NXC-201 45-patient safety and efficacy data selected for ASH 2026 oral presentation
- ➤ASH presentation scheduled for December 14, 2026, at 11:15 AM CDT
- ➤NXC-201 is being evaluated in potentially registrational NEXICART-2 trial
- ➤U.S. relapsed/refractory AL amyloidosis patients estimated at approximately 30,506 in 2026
– Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT –
LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) 68(th) Annual Meeting and Exposition to be held December 12-15, 2026, in New Orleans, LA.
Get started
Create a free account to read the full story.